Be Biopharma
Blood & Organ Banks · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Fl 3, Cambridge, Massachuse...Phone Number
(339) 345-3593Website
be.bioRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
3
6
6
6
2
About Be Biopharma
Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.Explore more
Be Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Be Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Be Biopharma has new funding data
Earning: See what the market has to say on Be Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Be Biopharma
Product Launch: Get notified when Be Biopharma launches new products
Be Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Be Biopharma is spiking on competitors!
Check if Be Biopharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Be Biopharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Be Biopharma
Compare insights from companies similar to Be Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Be Biopharma is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Be Biopharma is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Be Biopharma.
Be Biopharma financials insights
Gather financial insights about Be Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$52M
2024
Other Financing Round
$82M
2025
Series C
$92M
Be Biopharma Tech Stack
A closer look at the technologies used by Be Biopharma
Most Recent Scoops
Hiring Plans
Be Biopharma has more open roles in Engineering & Technical than it has had at any time in the past 12 months with an increased focus that include Technology Transfer, Project Management Software, and Current Good Manufacturing Practices (cGMPS), and experience with Statistics, Stakeholder Communications, Engineering Research, and Root Cause Analysis.
Hiring Plans
Open Position
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Be Biopharma News & Media
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting being held in New Orleans, May 13-17, 2025. Details regarding the Be Biopharma presentations at the conference are as follows: Oral Presentation Title: Ex Vivo Gene Editing of Autologous B Cells Produce Sustained LBe Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the appointment of Susan Abu-Absi, Ph.D., as Chief Operating Officer. With over 20 years of experience in strategic operations, product development and manufacturing in the biotechnology industry, Dr. Abu-Absi brings a wealth of knowledge and expertise to the role, positioning Be Bio for continued growth and opBe Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the publication in the journal Molecular Therapy of a manuscript highlighting first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of ex-vivo-generated plasma cells in non-human primates (NHPs) with intact immune systems. The study highlights the ability of these plasBe Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes participation from new investor Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures, among others. In conjunction with the financing, Melissa McCracken, Ph.D. of Nextech will jo
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding Be Biopharma
Sign Up For FreeTo access detailed company insights
Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to cre... Read More
